Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure.
Gheorghiade
Mihai
M
Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA. m-gheorghiade@northwestern.edu
Gattis
Wendy A
WA
Barbagelata
Alejandro
A
Adams
Kirkwood F
KF
Elkayam
Uri
U
Orlandi
Cesare
C
O'Connor
Christopher M
CM
D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin / Q000097:blood / Q000502:physiology*; D001552:Benzazepines / Q000627:therapeutic use; D018450:Disease Progression; D004311:Double-Blind Method; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006760:Hospitalization; D006801:Humans; D018579:Patient Selection; D011446:Prospective Studies; D017483:Receptors, Vasopressin / Q000502:physiology; D012107:Research Design; D000077602:Tolvaptan
D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D017483:Receptors, Vasopressin; D001127:Arginine Vasopressin; D000077602:Tolvaptan